Chinese drug discovery firm Hinova Pharmaceuticals Inc. has closed nearly 1 billion yuan ($147 million) in a Series C round of financing to support multi-centre clinical trials and the commercialisation of the firm’s drug candidates in China and internationally.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
